**CENTER FACT SHEET**

|  |  |
| --- | --- |
| **Name of Center** |  |

\*In case of a CCC Consortium, also name the individual CCC partner sites.

**Leadership** (from **Section A** in application)

|  |  |  |
| --- | --- | --- |
| **CCC Director** | **Function (scientific and/or clinical appointment)** | **Fulltime or part time,**  **% of working time designated to CCC** |
|  |  |  |
| **CCC Deputy Director(s)** | **Function (scientific or clinical appointment)** | **% of working time designated to CCC** |
|  |  |  |

Please adjust the table to fit your leadership structure accordingly.

**Catchment Area** (from **Section 6.1** in application)

|  |  |
| --- | --- |
|  | **Population (in Mio.)** |
| **Catchment area** |  |

**Basic Numbers for 2018** (from **Section 6.2** in application)

|  |  |  |  |
| --- | --- | --- | --- |
| **Details on the (University) Hospital** | **2018** | | |
|  | CCC Site 1\* | CCC Site 2\* | CCC Site X\* |
| Number of Departments/ Institutes |  |  |  |
| Employees |  |  |  |
| Hospital Beds |  |  |  |
| Inpatients1 |  |  |  |
| Outpatients2 |  |  |  |
| Patients receiving surgical interventions3 |  |  |  |
| Cancer Inpatients4 |  |  |  |
| Cancer Outpatients5 |  |  |  |

\*,1 **–** 5See Table 1 under 6.2

|  |  |  |  |
| --- | --- | --- | --- |
| **Field of Oncology** | **Number of Patients in 2018\*** | | |
|  | CCC Site 1\*\* | CCC Site 2\*\* | CCC Site X\*\* |
| Surgical Oncology\*\*\* |  |  |  |
| Radio-Oncology |  |  |  |
| Hemato-Oncology |  |  |  |
| Solid Tumor Medical Oncology |  |  |  |
| Pediatric Oncology |  |  |  |

\***–**\*\*\*See Table 2 under 6.2

**Cancer Patients** (from **Appendix 4** -Total A+B)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer Patients** | **2018** | | | |
|  | CCC Site 1\* | CCC Site 2\* | … | Total Consortium\* |
| **Newly diagnosed patients** |  |  |  |  |
| **Number of all cancer patients treated in the center** |  |  |  |  |

\*In case of a CCC Consortium only

**Local Funding of the CCC** (from **Section 9** in application)

|  |  |  |
| --- | --- | --- |
| **2018** | | |
| CCC Site 1\* | CCC Site 2\* | … |
| **Financial Support\*\* (in €)** |  |  |  |

\*In case of a CCC Consortium only

\*\*from e.g. university medical center, medical faculty, public health system - excluding standard clinic care

**Fields of Special Competence at the CCC** (from **Section 6.6** in application)

|  |
| --- |
| **Fields of Specific Competence in Oncology (max. 5; for consortia max. 10\*)** |
|  |
|  |
|  |
|  |
|  |

\*In case of a CCC Consortium, please specify at which CCC site the specific competence is available.

**Clinical Trials** (from **Section** **D1** in application)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **% of patients in clinical trials 2018** | | | | | | | |
| **Therapeutic (Phase I-III)** | | | | **Therapeutic + Supportive Care** | | | |
| CCC site 1\* | CCC site 2\* | ... | **Total Consortium\*** | CCC site 1\* | CCC site 2\* | **…** | **Total Consortium\*** |
| **Pediatric neo-plasms (< 18 y)** |  |  |  |  |  |  |  |  |
| **Hematolymphoid neoplasms**  **(adults only)** |  |  |  |  |  |  |  |  |
| **Solid tumors (adults only)** |  |  |  |  |  |  |  |  |

Percentage of cancer patients newly enrolled in prospective clinical cancer trials (in relation to the number of newly diagnosed patients; from Table 1 in Section D1)

\*In case of a CCC Consortium only

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **2018** | | | | | | | | | | | |
| **Number of Trials** | | | | **Number of patients enrolled** | | | | **Percentage of patients enrolled** | | | |
| Site 1\* | Site 2\* | … | **Total Cons**.\* | Site 1\* | Site 2\* | … | **Total Cons**.\* | Site 1\* | Site 2\* | … | **Total Cons**.\* |
| **Early Clinical Trials (Phase**  **I, I/II, II)** |  |  |  |  |  |  |  |  |  |  |  |  |
| **Therapeutic + Supportive Care Trials** |  |  |  |  |  |  |  |  |  |  |  |  |
| **Other Pros-pective Trials** |  |  |  |  |  |  |  |  |  |  |  |  |

Copy Table 2 from Section D1

\*In case of a CCC Consortium only

**Cancer Research Focuses - 5 TOP Cancer Research Programs** (select from **Section B 1.1** in application)

|  |  |
| --- | --- |
| **1.** |  |
| **2.** |  |
| **3.** |  |
| **4.** |  |
| **5.** |  |

**Third-Party Funding** (from **Appendix 9**)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Third-Party Funding** | **Amount in Euro** | | | |
|  | CCC Site 1\* | CCC Site 2\* | … | Total Consortium\* |
| **Newly granted in 2018** (Sum II) |  |  |  |  |
| **Total amount available in 2018** (Sum I) |  |  |  |  |

\*In case of a CCC Consortium only

**Tumor-/Biobank(s)** (from **Section** **C3**)

|  |  |  |  |
| --- | --- | --- | --- |
| **Total number of all cancer patients\* whose specimens are**  **stored in the biobank** | | | |
|
| CCC Site\*\* | **Fresh Frozen Tissue** | **FFPE Specimens** | **Liquid Samples** | **Living (Organoid) Samples** |
| CCC Site 1 |  |  |  |  |
| CCC Site 2 |  |  |  |  |
| … |  |  |  |  |
| Total Consortium |  |  |  |  |

\*Only patients who were treated for a principal diagnosis of cancer may be counted. Do not include

any patient more than once, unless he/she has been treated for more than one malignancy.

\*\*In case of a CCC Consortium, indicate the numbers for the individual partner sites and for the entire consortium.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Oncology-related requests to the biobank** | | | | | | | | | | | |
| **Number of requests1** | | | | **Number of approvals** | | | | **Number of successfully completed requests2** | | | |
|  | Site 1\* | Site 2\* | Site X\* | TC\* | Site 1\* | Site 2\* | Site X\* | TC\* | Site 1\* | Site 2\* | Site X \* | TC\* |
| 2016 |  |  |  |  |  |  |  |  |  |  |  |  |
| 2017 |  |  |  |  |  |  |  |  |  |  |  |  |
| 2018 |  |  |  |  |  |  |  |  |  |  |  |  |

1Irrespective of the kind of biomaterial

2Include here only requests which were approved and which led to a supply of biomaterial.

\*In case of a CCC Consortium: please indicate the numbers for the individual CCC sites as well as for the entire consortium

(Site 1 – X: individual CCC partner site; TC: Total Consortium).

**Important Publications** (from **Appendix 8**)

**List the 5 (for consortia: 10) most important publications (since 2015; most recent first) resulting from the above mentioned research programs. Please highlight joint publications of consortium partners.**

|  |  |  |  |
| --- | --- | --- | --- |
| **First Author et al.** | **Title** | **Journal** | **Year** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |